SAN FRANCISCO, CA--(Marketwired - August 18, 2016) - Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. (NYSE MKT: ATNM) is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching.
Included in this article is: Actinium Pharmaceuticals Inc.
Can you give an introduction to Actinium Pharmaceuticals Inc. and its mission?
Sandesh Seth: Actinium has the simple mission of using radioimmunotherapies to "nuke cancer," with a focus on cancers with high unmet needs, where traditional cancer therapies do not work. Most people are unfamiliar with radioimmunotherapy, but they are familiar with its two core components, which are monoclonal antibodies that target specific markers on cancer cells, and radioisotopes that kill cancer cells by emitting radiation energy. The result of this combination is a targeted, powerful cancer killing therapy that does not have many of the side effects and toxicities seen with traditional cancer therapies, such as chemotherapy and external beam radiation. We believe Actinium is a leader in the field of radioimmunotherapy and we are very excited for the future.
Continue reading this article: Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
1) Actinium Pharmaceutical Inc. is a sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclaimers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
2) Sandesh Seth had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Sandesh Seth and not of Streetwise Reports or its officers.
3) Sandesh Seth: I was not paid by Streetwise Reports to participate in this management discussion. I had the opportunity to review this for accuracy and am responsible for the content. I or my family own shares of the following companies mentioned in this discussion: Actinium Pharmaceuticals and Spectrum Pharmaceuticals.
Please see the end of the article for the complete disclosure: Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs